Abstract
To assess the cost-effectiveness of abatacept compared to different biologic treatment strategies for moderate to severe rheumatoid arthritis based on current medical practices in Canada. A model was constructed to assess the cost-effectiveness of various biologic treatments over a 2-year time horizon, using two effectiveness endpoints: “low disease activity state” (LDAS) and “remission”. Abatacept, as first biologic agent after an inadequate response to DMARDs, provides greater treatment success rate for achieving LDAS (29.4% versus 15.6%) and remission (14.8% versus 5.2%), and appears significantly more cost-effective compared to the sequential use of anti-TNF agents (p < 0.001). Abatacept, as second biologic agent after an inadequate response to one anti-TNF agent, provides greater treatment success rate for achieving LDAS (17.1% versus 10.2%) and remission (7.4% versus 3.9%) and appears significantly more cost-effective compared to the sequential use of anti-TNF agents (p < 0.001). Abatacept is a cost-effective strategy in patients with an inadequate response to DMARDs or to one anti-TNF agent.
Similar content being viewed by others
References
Pisetsky D, St Clair E (2001) Progress in the treatment of rheumatoid arthritis. JAMA 286:2787–2790
Weinblatt M, Kremer J, Bankhurst A, Bulpitt K, Fleischmann R, Fox R, Jackson C, Lange M, Burge D (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259
Weinblatt M, Keystone E, Furst D, Moreland L, Weisman M, Birbara C, Teoh L, Fischkoff S, Chartash E (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45
Lipsky P, van der Heijde D, St Clair E, Furst D, Breedveld F, Kalden J, Smolen J, Weisman M, Emery P, Feldmann M, Harriman G, Maini R, Group A-TNFTiRAwCTS (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602
Redlich K, Schett G, Steiner G, Hayer S, Wagner EJSS (2003) Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 48:3308–3319
Klinkhoff A (2004) Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs 64:1267–1283
Smolen J, Steiner G (2003) Therapeutic strategies for rheumatoid arthritis. Nature Reviews 2
Hyrich K, Lunt M, Watson K, Symmons D, Silman A (2007) Outcomes after switching from one anti-tumor necrosis factor agent to a second anti-tumor necrosis factor agent in patients with rheumatoid arthritis. Arthritis Rheum 56:13–20
Flendrie M, Creemers M, Welsing PMJ, den Broeder AA, van Riel PLCM (2003) Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 62:30–33
Pugner KM, Scott DI, Holmes JW, Hieke K (2000) The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 29:305–320
Genovese M, Becker J, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty D, Dougados M (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114–1123
Kremer J, Genant H, Moreland L, Russel A et al (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144:865–876
Stahl J (2008) Modelling methods for pharmacoeconomics and health technology assessment, an overview and guide. Pharmacoeconomics 26:131–148
Makinen H, Kautiainen H, Hannonen P, Tuulikki S (2005) Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria. A 5-year followup study. J Rheumatol 32:796–800
American College of Rheumatology (2002) Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 46:328–346
Fransen J, Van Riel PLCM (2005) The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 23:S93–S99
Welsing PMJ, van Gestel AM, Swinkels HL, Keimeney LALM, Van Riel PLCM (2001) The relationship between disease activity, joint destruction and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 44:2009–2017
Welsing PMJ, Severens JL, Hartman M, van Gestel AM, van Riel PLCM, Laan RFJM (2006) The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis. Pharmacoeconomics 24:1011–1020
Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S, Investigators ftTS (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54:1063–1074
Kremer J, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, Steinfeld S, Tindall E, Becker J, Li T, Nuamah I, Aranda R, Moreland L (2005) Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept—12 month results of a phase II double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:2263–2271 Aug
Genovese M, Schiff M, Luggen M, Becker J, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M (2007) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy. Ann Rheum Dis (online) Oct 5:doi:10.1136/ard.2007.074773
Hervey P, Keam S (2006) Abatacept. Biodrugs 20:53–61
Weinblatt M, Combe B, Covucci A, Aranda R, Becker J, Keystone E (2006) Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs. A one year randomized placebo-controlled study. Arthritis Rheum 54:2807–2816
Haraoui B, Cameron L, L’Archevêque J, Ouellet M, Choquette D, Raynauld J (2007) Clinical response to a second or third anti-TNF agent after discontinuation of the first. Implications for therapeutic decision-making. 4th Canadian Association for Population Therapeutics (CAPT) Congress Halifax
Navaro F, Marsal S, Gomez-Reino J, Perez-Pampon E (2006) EULAR response and drug survival in clinical practice in RA patients treated with anti-TNF therapy: results of an observational, prospective, cohort study in Spain. Ann Rheum Dis 65:333
Van Vollenhoven R, Cullinane Carli C, Bratt J, Klareskog L (2006) Six-year report of the STURE registry for biologicals in rheumatology: satisfactory overall results, but plenty of room for improvement. Ann Rheum Dis 65:511
Gomez-Reino J, Carmona L, Group tB (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Research & Therapy 8:(doi:10.1186/ar1881); http://arthritis-research.com/content/1188/1181/R1129
Canadian Fitness and Lifestyle Research Institute (1995) Physical Activity Monitor. http://wwwdflrica/cflri/pa/surveys/95survey/95surveyhtml
Katchamart W, Li X, Bombardier C (2006) Direct and indirect costs of rheumatoid arthritis are strongly correlated with disease activity and functional status. ACR/ARHP 625
Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C (2004) The economic burden associated with osteoarthritis, rheumatoid arthritis and hypertension: a comparative study. Ann Rheum Dis 63:395–401
Welsing PMJ, Severens JL, Harman M, van Riel PLCM, Laan RFJM (2004) Modeling the 5-year cost-effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum (Athritis Care & Research) 51:964–973
Emery P (2004) Review of health economics modelling in rheumatoid arthritis. Pharmacoeconomics 22:55–69
Bansback N, Regier D, Ara R, Brennan A, Shojania K, Esdaile J, Anis Aslam H, Marra Carlo A (2005) An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 65:473–496
Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, Wong J, Gabriel S, Group obotOER (2003) Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a reference case. J Rheumatol 30:891–896
Wells G, Boers M, Shea B, Brooks P, Simon L, Strand C, Aletaha D, Anderson J, Bombardier C, Dougados M, Emery P, Felson D, Fransen J, Furst D, Hazes J, Johnson K, Kirwan J, Landewé R, Lassere M, Michaud K, Suarez-Almazor M, Silman A, Smolen J, Van der Heijde D, van Riel P, Wolfe F, Tugwell P (2005) Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 32:2016–2024
Lyseng-Williamson KA, Plosker GL (2004) Etanercept: a pharmacoeconmic review of its use in rheumatoid arthritis. Pharmacoeconomics 22:1071–1095
Doan QV, Chiou CG, Dubois RW (2006) Review of eight pharmacoeconomic studies of the value of biologic DMARDS (adalimumab, etanercept and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 12:555–569
Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, Symmons D (2007) Modelling the cost-effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology 46:1345–1354
Suarez-Almazor M, Conner-Spady B (2001) Rating of arthritis health states by patients, physicians, and the general public. Implications for cost-utility analyses. J Rheumatol 28:648–656
Duru G, Auray JP, Beresniak A, Lamure M, Paine A, Nicoloyannis N (2002) Limitations of the methods used for calculating quality-adjusted life-year values. Pharmacoeconomics 20:463–473
Mc Gregor M, Caro J (2006) QALYs: Are they helpful to decision makers? Pharmacoeconomics 24:947–952
Jorstad I, Kirstiansen I, Uhlig T et al (2005) Performance of four utility measures in 1041 patients with rheumatoid arthritis (RA): well correlated but differing widely in valuing health states. Arthritis Rheum 52:S660
Ariza-Ariza R, Hernández-Cruz B, Carmona L, Ruiz-Montecinos MD, Ballina J, Navarro-Sarabia F, Group CaQoLiRAS (2006) Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol. Arthritis Rheum (Arthritis Care Res) 55:751–756
Beresniak A, Russell A, Haraoui B, Bessette L, Bombardier C, Duru G (2007) Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol 34:2193–2200
Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B, Rodríguez-Arboleya L, Navarro-Compán V, Toyos J (2007) Dose escalation of the anti-TNF-α agents in patients with rheumatoid arthritis. A systematic review. Rheumatology 46:529–532
Haraoui B, Cameron L, Ouellet M, White B (2006) Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 33:31–36
Wolbink G, Vis M, Lems W, Voskuyl A, de Groot E, Nurmohamed M, Stapel S, Tak P, Aarden L, Dijkmans B (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54:711–715
Berger A, Edelsberg J, Li T, Maclean J, Oster G (2005) Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother 39:2021–2025
Stern R, Wolfe F (2004) Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 31:1538–1545
Fitzcharles M, Clayton D, Menard H (2002) The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J Rheumatol 29:2525–2530
Agarwal S, Maier A, Chibnik L, Coblyn J, Fossel A, Lee R, Fanikos J, Fiumara K, Lowry C, Weinblatt M (2005) Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum (Arthritis Care Res) 53:872–878
Acknowledgment
We are grateful to Dr Claire Bombardier, MD, FRCPC, Mount Sinai Hospital, University of Toronto (Canada) for providing the data on the Ontario cohort for the calculation of the cost per DAS categories.
Disclosures
Anthony Russell, Ariel Beresniak, Louis Bessette, Boulos Haraoui, Proton Rahman and Carter Thorne have received fees and honorarium to attend Steering Committee meetings and to defray travel expenses reimbursement from Bristol-Myers Squibb.
Ross Maclean and Danielle Dupont are employees of Bristol-Myers Squibb.
Source of funding
The work has been sponsored by Bristol-Myers Squibb International.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Russell, A., Beresniak, A., Bessette, L. et al. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol 28, 403–412 (2009). https://doi.org/10.1007/s10067-008-1060-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-008-1060-4